Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)

Trial Profile

Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Acute nonlymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Feb 2015 Planned End Date changed from 1 Aug 2021 to 1 Jan 2022 as reported by ClinicalTrials.gov record.
    • 11 Feb 2015 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top